Background Frailty is a clinical syndrome characterized by diminished strength, endurance, and physiological function that significantly increases vulnerability to adverse health outcomes, including infections. In the context of COVID-19, frailty has emerged as a critical risk factor for severe disease, complications, and mortality, particularly in older adults. The severity and fatality rates among the geriatric group were notably high, as the virus's pathogenesis, marked by prolonged inflammation, contributed to increased morbidity and mortality in this age group. The study was conducted to explore the role of frailty in influencing mortality among the elderly affected by COVID-19. Objective The objective of this study was to identify the association between frailty and mortality in COVID-19-affected elderly patients. Methods We conducted a prospective observational study among elderly patients who tested positive for COVID-19 and received treatment in a tertiary care hospital. Data were collected from 250 patients from March 2021 to December 2021. Lab parameters, the necessity for mechanical ventilation, the need for oxygen use, and the number of days of hospital stay were recorded. The Clinical Frailty Score (CFS) was used to evaluate frailty. The chi-square test with Fisher's exact test was used to assess the association between frailty and mortality in the data set. Multivariate binary logistic regression was employed to identify the most significant predictors of mortality. Results Among the 250 patients, 159 (63.6%) survived and were discharged, while 91 (36.4%) succumbed to the illness. Fifty-eight patients were not identified as frail, and there were no deaths in the group. On the contrary, among the 192 COVID-positive patients who were identified as frail, 91 (47.4%) patients died, and 101 (52.6%) patients were alive. This depicted the association between frailty and mortality in COVID-19 geriatric patients. While assessing comorbidities, malignancy (53.3%, p-value = 0.009) and chronic kidney disease (CKD) (43.3%) had a significant association with mortality. Symptoms like fever (43.6%), dyspnea (68.6%), myalgia (20%), and altered sensorium (84%) showed a strong correlation with mortality (p<0.001). Frailty was a significant predictor of mortality, with 47.4% of frail patients not surviving (p<0.001). Biochemical markers including leukocytosis (64.8%), neutrophilia (65.3%), eosinopenia (66.9%), anemia (57.8%), hypoalbuminemia (63.5%), hypoproteinemia (70.1%), elevated alanine aminotransferase (ALT) (66%), aspartate aminotransferase (AST) (65.2%), alkaline phosphatase (ALP) (67.5%), elevated creatinine (68.9%), hypernatremia (100%), hyperkalemia (80%), and elevated D-dimer (44.7%) were all significantly linked to mortality. Additionally, patients requiring oxygen (65%), ventilation (96.8%), or bilevel positive airway pressure (BiPAP) (77.8%) had higher mortality rates. A shorter length of hospital stay was also associated with increased mortality (24%). Conclusion Frailty, combined with certain comorbidities such as cancer and CKD, along with various clinical and biochemical markers, played a significant role in predicting mortality among geriatric COVID-19 patients. Incorporating frailty assessments into routine evaluations for elderly COVID-19 survivors could be beneficial. Early detection and focused management of these high-risk factors are essential for improving outcomes in frail patients within tertiary care settings.
Keywords: clinical frailty; covid-19 india; elderly patients; mortality predictors; sars-cov-2.
Copyright © 2024, Srivatsa et al.